Prostate cancer is the second most common cancer in men worldwide and causes over 250,000 deaths each year 1 . Overtreatment of indolent disease also results in significant morbidity 2 . Common genetic alterations in prostate cancer include losses of NKX3.1 (8p21) 3,4 and PTEN (10q23) 5,6 , gains of AR (the androgen receptor gene) 7,8 and fusion of ETS family transcription factor genes with androgen-responsive promoters 9-11 . Recurrent somatic base-pair substitutions are believed to be less contributory in prostate tumorigenesis 12,13 but have not been systematically analyzed in large cohorts. Here, we sequenced the exomes of 112 prostate tumor and normal tissue pairs. New recurrent mutations were identified in multiple genes, including MED12 and FOXA1. SPOP was the most frequently mutated gene, with mutations involving the SPOP substrate-binding cleft in 6-15% of tumors across multiple independent cohorts. Prostate cancers with mutant SPOP lacked ETS family gene rearrangements and showed a distinct pattern of genomic alterations. Thus, SPOP mutations may define a new molecular subtype of prostate cancer.
Prostate cancer is the second most common cancer in men worldwide and causes over 250,000 deaths each year 1 . Overtreatment of indolent disease also results in significant morbidity 2 . Common genetic alterations in prostate cancer include losses of NKX3.1 (8p21) 3, 4 and PTEN (10q23) 5, 6 , gains of AR (the androgen receptor gene) 7, 8 and fusion of ETS family transcription factor genes with androgen-responsive promoters [9] [10] [11] . Recurrent somatic base-pair substitutions are believed to be less contributory in prostate tumorigenesis 12, 13 but have not been systematically analyzed in large cohorts. Here, we sequenced the exomes of 112 prostate tumor and normal tissue pairs. New recurrent mutations were identified in multiple genes, including MED12 and FOXA1. SPOP was the most frequently mutated gene, with mutations involving the SPOP substrate-binding cleft in 6-15% of tumors across multiple independent cohorts. Prostate cancers with mutant SPOP lacked ETS family gene rearrangements and showed a distinct pattern of genomic alterations. Thus, SPOP mutations may define a new molecular subtype of prostate cancer.
We performed exome capture followed by paired-end massively parallel sequencing on genomic DNA from 112 prostate adenocarcinomas and matched normal samples. We focused on treatment-naïve radical prostatectomy specimens from US and Australian subjects that spanned a range of grades, stages and risks of recurrence (Online Methods and Supplementary Table 1 ). The baits for exon capture targeted 98.2% of genes in the Consensus CDS (CCDS) database. A mean coverage depth of 118× per sample was achieved, with 89.2% of targets covered at a depth of ≥20× ( Supplementary Fig. 1 and Supplementary Table 2) . DNA from tumors and normal samples was also analyzed by Affymetrix SNP 6.0 arrays to detect somatic copy-number alterations. In addition, transcriptome sequencing (RNA-seq) was performed on 22 exome-sequenced tumors and 41 independent samples (Supplementary Fig. 2) .
We identified 5,764 somatic mutations that were present in DNA from tumors but absent in DNA from peripheral blood or non-cancerous prostate tissue (Supplementary Table 3) . Of these variants, 997 occurred in a single tumor that harbored a frameshift mutation of the mismatch repair gene MSH6 (Supplementary Fig. 3 ). Excluding this highly mutated sample, the remaining tumors harbored a median of 10 silent and 30 non-silent mutations (range 10 to 105 total mutations) or ~1.4 mutations per megabase of DNA covered ( Supplementary  Fig. 3 ). Analysis of 229 non-silent mutations by mass spectrometry genotyping validated 95.6% of variants with allelic fraction of ≥0.2 (confidence interval (CI) = 92-98%) (Supplementary Table 3 ). The mutation rate of this cohort exceeded that of seven published prostate tumor genomes (0.9 mutations per megabase) 14 , perhaps because increased exome sequence coverage improved the detection of variants present at lower allelic fractions.
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We searched for genes that harbored more nonsynonymous mutations than expected by chance given gene size, sequence context and the frequency of mutations for each tumor (Fig. 1a and Supplementary Table 4) . Twelve genes were enriched for mutations at q value < 0.1, the majority of which are highly expressed at the transcript level in prostate tumors ( Supplementary Fig. 4) . The identification of PIK3CA, TP53 and PTEN confirmed that our approach detected alterations known to promote tumorigenesis in prostate cancer and other malignancies. We also found evidence of enrichment for mutations in the PTEN pathway, cell cycle regulatory machinery and other gene sets (Supplementary Table 5 ) 12 .
The most frequently mutated gene was SPOP (in 13% of tumors; Fig. 1) , which encodes the substrate-binding subunit of a Cullin-based E3 ubiquitin ligase 15, 16 . Although isolated SPOP mutations have been reported in prostate cancer 14, 17 , this gene has not previously been found to be mutated at a significant frequency in any malignancy. Several genes not previously known to undergo somatic alteration in prostate cancer were enriched for mutations, including FOXA1, MED12, THSD7B, SCN11A and ZNF595. The CDKN1B gene encoding p27 Kip1 was somatically mutated in 3 samples and deleted in 16 others (Fig. 1b) . p27 Kip1 constrains prostate tumor growth in mice 18 and CDKN1B harbors a germline prostate cancer risk allele 19 , but somatic substitutions had not previously been observed in this cell cycle regulator. Infrequent mutations were also detected in multiple proto-oncogenes, tumor suppressors and chromatin-modifying enzymes (Supplementary Table 4 and Supplementary Note).
The forkhead transcription factor gene FOXA1 harbored non-silent mutations in 4 of 111 exomes and 4 of 41 independent RNA-seq samples. The FOXA1 protein is required for epithelial cell differentiation in the mouse prostate 20 and promotes cell cycle progression in castration-resistant prostate cancer 21 . Notably, FOXA1 modulates androgen receptor-driven transcription 22 and activates expression of CDKN1B 23 . Mutations strictly affected residues in the forkhead domain (Supplementary Table 4 ) that resides near the DNA-binding surface (Fig. 2a) 24 . The clustered nature of these mutations suggests that they may disrupt binding of FOXA1 to DNA targets.
Mutations affecting MED12 were observed in 6 of 111 exomes, with a recurrent L1224F variant (encoded by c.3670C>T or c.3669_3670TC>GT) being identified in five samples ( Fig. 2b and Supplementary Table 4 ). MED12 encodes a subunit of the mediator complex and the cyclin-dependent kinase 8 (CDK8) subcomplex that regulates basal and stimulus-specific transcriptional programs [25] [26] [27] . Recently, MED12 mutations were reported in 70% of uterine leiomyomas 28 , benign stromal tumors of the smooth muscle lineage. Mutations in prostate cancer affected distinct codons from those in leiomyoma and occurred in epithelial cells rather than stroma, as determined by laser-capture microdissection (LCM) (Supplementary Fig. 5 ). MED12 mutations may conceivably perturb CDK8-dependent modulation of transcriptional programs linked to p53 and androgen signaling 26, 27 . 24 and are highlighted in red. (b) Recurrent MED12 alterations in prostate cancer (red) are distinct from those reported in uterine leiomyeoma (black) 28 . Domains of MED12 are denoted as previously 25 ; L, leucine-rich domain; LS, leucine-and serine-rich domain; PQL, proline-, glutamine-, leucine-rich domain; OPA, opposite paired domain. Multispecies conservation of the mutated sites is shown below each alteration in prostate cancer.
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Although SPOP mutations were originally reported in genomic studies of prostate cancer (Supplementary Table 6 ) 14, 17 , their prevalence and functional relevance remained unknown. We therefore sequenced this gene in multiple additional cohorts comprising over 300 primary tumors and metastases from individuals in the United States and Europe. Using RNA-seq and Sanger sequencing of tumor and matched germline DNA, recurrent heterozygous SPOP substitutions were identified in 6-13% of primary prostate adenocarcinomas ( Fig. 3a, Supplementary Fig. 6 and Supplementary Table 7) . No mutations were identified in 36 benign prostate tissue samples, 5 samples of prostate stroma or 6 common prostate cell lines. SPOP mutations were also found in 6 of 41 individuals with metastatic disease (14.5%) ( Fig. 3a and Supplementary Table 7) . Thus, SPOP mutations occurred at a frequency of 6-15% across localized and advanced prostate tumors.
All SPOP mutations affected conserved residues in the structurally defined substrate-binding cleft ( Fig. 3b and Supplementary Fig. 7 ) 16 . Several recurrently altered residues have key roles in substrate interaction; moreover, alteration of Tyr87, Trp131 and Phe133 disrupted substrate binding in vitro 16 . These results strongly suggest that SPOP mutations in prostate cancer are biologically consequential. To test this hypothesis, we examined the consequences of mutant SPOP protein expression or SPOP knockdown on tumorigenic phenotypes in vitro. Prostate cancer cells transfected with the most common SPOP mutant (the F133V variant) or with SPOP siRNA showed increased invasion compared to controls (Fig. 3c-e and Supplementary Fig. 8 ), but cell growth and viability were largely unaltered (Supplementary Fig. 9 ). The SPOP-CUL3 complex affects a variety of substrates that participate in multiple pathways, including hedgehog, c-Jun N-terminal kinase (JNK) and steroid receptor signaling cascades [29] [30] [31] . SPOP undergoes amplification in other malignancies and may be overexpressed in renal cell carcinoma 29 ; however, multiple prostate cancer cohorts showed no evidence of SPOP amplification or upregulation (Fig. 1b and Supplementary Figs. 10 and 11) . Prostate cancerassociated SPOP mutations may conceivably result in de novo gainof-function alterations (for example, interaction with a distinct substrate profile), dominant-negative effects or more subtle alterations in substrate specificity. Further studies are necessary to determine the specific ubiquitin ligase functions and cellular pathways deregulated by SPOP mutation in prostate cancer.
Notably, all exomes with SPOP mutations lacked the TMPRSS2-ERG fusion or other ETS family gene rearrangements present in up to 50% of prostate cancers (Fig. 4 and Supplementary Fig. 12 ) 11, 32 . This mutually exclusive relationship between SPOP mutation and ERG rearrangement (P < 0.001, Fisher's exact test) was confirmed in evaluable samples across all five cohorts tested (Supplementary Fig. 12 ), even within an individual prostate tumor (Supplementary Fig. 13 ). Thus, SPOP mutation and ETS family gene fusions may represent early and divergent driver events in prostate carcinogenesis. SPOP mutations were identified in LCM-analyzed high-grade intraepithelial neoplasia (HG-PIN) adjacent to invasive adenocarcinoma, providing further support for the idea that SPOP mutation comprises an early event in prostate tumorigenesis (Supplementary Fig. 14) .
In light of previous studies suggesting that prostate cancer may be classified by co-occurring genomic alterations 12, 33, 34 , we investigated whether tumors with SPOP mutations were enriched for other genomic lesions (Fig. 4) . Recurrent somatic deletions at 5q21 and 6q21 were found to be enriched in these tumors (P = 1.4 × 10 −11 and 3.4 × 10 −7 , respectively, Fisher's exact test), both in the cohort used for wholeexome sequencing and in an independent prostate cancer collection (Fig. 4 and Supplementary Table 8) . Thus, loss of tumor suppressor genes in these regions may cooperate with SPOP mutation to promote tumorigenesis. The relevant 5q21 locus contains CHD1, which encodes a chromatin-modifying enzyme that also undergoes disruptive rearrangements in prostate cancer 14 . The 6q21 region encompasses several genes, including FOXO3, a FOXA1 homolog that has previously been implicated in prostate carcinogenesis and progression 35 , and PRDM1, a tumor suppressor in lymphoma 36 . In contrast, TP53 lesions were generally absent in tumors with SPOP mutations (P = 0.015, Fisher's exact test), despite the fact that this tumor suppressor was recurrently mutated and deleted (Fig. 1) . SPOP mutations also trended inversely with point mutations and/or copy-number loss involving the PTEN locus in primary tumors (P = 0.044, Fisher's exact test) (Fig. 4) ; this pattern was supported by FISH analysis for PTEN deletion Fig. 15 ). Tumors with SPOP mutations also lacked PIK3CA mutations (Fig. 4) . Although the inverse relationship between SPOP mutations and PTEN and PIK3CA alterations was observed in primary tumors (P = 0.041, Fisher's exact test), these events co-occurred more frequently in metastatic tumors (Supplementary Fig. 15 ). Further studies are needed to determine whether these genetic relationships also occur in other populations of affected individuals and to elucidate the biological interactions that may underlie this phenomenon. Taken together, these results suggest that SPOP mutations may anchor a distinct genetic subtype of ETS fusion-negative cancers.
In summary, whole-exome sequencing has identified genes that are recurrently mutated in prostate cancer. These efforts have also revealed a distinct ETS fusion-negative subclass of prostate cancer characterized by recurrent SPOP mutations and enriched for both 5q21 and 6q21 deletions. In the future, this expanded genetic framework may articulate new mechanisms of carcinogenesis that inform both disease modeling and patient stratification for clinical trials of experimental agents. Together with additional comprehensive analyses of the prostate cancer genome, epigenome and transcriptome, these systematic approaches should illuminate the landscape of alterations that underlie disease biology and therapeutic vulnerability in this common and clinically heterogeneous malignancy.
URLs. CCDS, http://www.ncbi.nlm.nih.gov/CCDS/; Protein Data Bank, http://www.pdb.org/.
METHOdS
Methods and any associated references are available in the online version of the paper. Accession codes. Binary sequence alignment/map (BAM) files and SNP array data were deposited in the database of Genotypes and Phenotypes (dbGaP; phs000447.v1.p1). 
Note: Supplementary information is available in the online version of the paper.
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DNA extraction and exome sequencing. Slides for hematoylin and eosin staining were cut from all frozen tissue blocks and examined by a board-certified pathologist to select for high-density cancer foci with <10% stroma or other non-cancerous material to ensure high purity of cancer DNA. Biopsy cores were then taken from the corresponding frozen tissue block for DNA extraction. From each sample, 25-30 mg of tissue was homogenized. DNA was extracted from homogenate and quantified using Picogreen dsDNA Quantitation Reagent (Invitrogen). Samples were separated on agarose gels (E-Gel, Invitrogen) to assess structural integrity. All DNA samples were stored at −20 °C. Ancestry analysis of sequenced samples is shown in Supplementary Figure 16 .
Whole-exome capture libraries were constructed from 100 ng of DNA from tumors and normal tissue after sample shearing, end repair, phosphorylation and ligation to barcoded sequencing adaptors 37 . Ligated DNA was size selected for lengths between 200-350 bp and subjected to exonic hybrid capture using SureSelect v2 Exome bait (Agilent). Samples were multiplexed and sequenced on multiple Illumina HiSeq flow cells for average target exome coverage of 118×.
Copy-number analysis. DNA from tumors and normal tissue was analyzed by Affymetrix SNP 6.0 arrays to detect regions of somatic copy-number alteration (Supplementary Table 9 ). Quality control, segmentation and copy-number analysis were performed as previously described 33 , with one additional step aimed at diminishing the number of recurrent lesions possibly caused by germline signal: we applied the same detection pipeline to the DNA samples from normal tissue alone. All peaks detected in both analyses were excluded from the list of recurrent somatic copy-number aberrations. The remaining lesions with Genomic Identification of Significant Targets in Cancer (GISTIC) q value of <0.1 were included in analysis of copy-number alterations associated with mutated genes. Two-tailed Fisher's exact tests were applied for all association tests.
Sequence data processing and quality control. Exome sequence data processing and analysis were performed using pipelines at the Broad Institute 14, 38, 39 . A BAM file aligned to the hg19 human genome build was generated from Illumina sequencing reads for each tumor and normal sample by the Picard pipeline. The Firehose pipeline was used to manage input and output files and submit analyses for execution by GenePattern 40 .
Quality control modules in Firehose were used to compare genotypes derived from Affymetrix arrays and sequencing data to ensure concordance. Genotypes from SNP arrays were also used to monitor for low levels of crosscontamination between samples from different individuals in sequencing data using the ContEst algorithm 41 .
Mutation calling and identification of significantly mutated genes. The MuTect algorithm from the Broad Institute Genome Analysis Toolkit was used to identify somatic single-nucleotide variants (SSNVs) in targeted exons 39, 42 . MuTect identifies candidate SSNVs by Bayesian statistical analysis of bases and their qualities in the tumor and normal BAM files at a given genomic locus. We required a minimum of 14 reads covering a site in the tumor and 8 reads in the normal sample for mutation calling. We determined the lowest allelic fraction at which SSNVs could be detected on a per-sample basis, using estimates of cross-contamination from the ContEst pipeline 41 . Small somatic insertions and deletions (indels) were detected using the Indelocator algorithm after local realignment of sequences from tumors and normal samples 42 .
The MutSig algorithm from the Broad Institute was applied to identify genes or gene sets that were significantly enriched for mutations, given sequence context and genomic territory 14, 39, 42 . For each gene, we calculated the probability of detecting the observed constellation of mutations or a more extreme one, given the background mutation rates calculated across the data set. This P value was then adjusted for multiple hypotheses testing (Benjamini-Hochberg procedure) to obtain a q value. Mutations in significantly mutated genes and the others described were manually reviewed by examination of BAM files in the Integrative Genomics Viewer (IGV) 43 .
Validation of selected mutations by mass spectrometry genotyping. We chose 240 non-silent mutations (231 SSNVs and 9 indels) across 48 pairs of tumor and normal samples to validate by mass spectrometry genotyping using the iPLEX platform (Sequenom). We targeted 74 mutations in significantly mutated genes or gene sets with q value of <0.1 and mutations reported in COSMIC. The remaining 166 non-silent mutations were chosen at random. Because the rate of validation using this technology is significantly lower when the mutant allele is present at low allelic fraction 14, 38 , we attempted to validate only mutations with allelic fraction of ≥0.2 (where 20% of sequence reads from the tumor contained the mutation).
Of the 240 assays attempted, 228 gave successful genotype calls, and 218 somatic mutations were confirmed (Supplementary Table 3) . All events called in the tumor were absent from the corresponding normal sample. The overall accuracy for mutation calling was 95.6% (Clopper-Pearson 95% CI = 92-98%), in close agreement with previous studies 14, 38, 39 .
Mutation annotation. Somatic point mutations and indels were annotated using information from publicly available databases, including the UCSC Genome Browser's UCSC Genes track 44 Mutations were classified as heterozygous or homozygous using the ABSOLUTE algorithm 50 . ABSOLUTE integrates genome-wide copy-number data from SNP arrays and the allelic fraction values of somatic mutations to model gene and mutation copy number in a tumor. Only a subset of tumors contained sufficient copy-number alterations to permit analysis. Mutations in these tumors were annotated as heterozygous or homozygous and clonal or subclonal. Mutation multiplicity, equal to the average number of copies of a mutation per cancer cell, was also calculated (Supplementary Figs. 17 and 18 and Supplementary Table 10) .
RNA extraction and RNA-seq sample prep, sequencing and processing. RNA was extracted from the frozen cancer tissue using TRIzol (Invitrogen), according to the manufacturer's protocol. Total RNA was prepared in accordance with Illumina's sample preparation protocol for paired-end sequencing of mRNA, as previously described 51 . Paired-end reads were aligned to the human genome (hg18) using ELAND, as previously described 51 . Data were visualized using IGV 43 , and candidate mutations were identified in SPOP coding regions.
DNA extraction and SPOP genotyping. DNA was extracted using phenolchloroform and purified by an ethanol precipitation method, as previously described 14 . Direct Sanger sequencing of putative SPOP somatic mutations in all tumor-blood pairs was performed by standard methods, following PCR amplification using specific primers. The sequences of the primers used for amplifying and sequencing SPOP are given (Supplementary Table 11 ).
Laser capture microdissection. Tissue sections (5 µm thick) were cut, fixed and stained on membrane-coated slides and were dissected with the ArcturusXT LCM Instrument (Life Technologies). Tissue staining and LCM were performed as described 52 . A combination of inferred capture and UV laser cutting was carried out to best recover a precise subset of cells. DNA was amplified with the Whole Genome Amplification kit (WGA4), as suggested by the manufacturer for the single-cell approach (Sigma-Aldrich). Standard PCR was used for targeted enrichment of SPOP exons 6 and 7, and Sanger sequencing was performed.
FISH. ETS rearrangement status and PTEN deletion status were assessed on tissue slides from the same tumor nodule used for RNA and DNA extraction. FISH methods to detect TMPRSS2-ETS gene fusions have been previously described 9, 11 . We used ERG, ETV1, ETV4 and ETV5 break-apart FISH assays to confirm gene rearrangement on the DNA level 53 . To assess the status of PTEN, we used a locus-specific probe and a reference probe, as previously described 14 . The sequences of all FISH probes are listed (Supplementary Table 12 ).
Quantitative RT-PCR. RNA was extracted using TRIzol reagent, subjected to DNase treatment (DNA-free Kit; Applied Biosystems) according to the manufacturer's instructions and used in quantitative RT-PCR. Quantitative RT-PCR was performed using the ABI 7500 Real-Time PCR System (Applied Biosystems), following the manufacturer's RNA-to-CT 1-step protocol. Each target was run in triplicate, and expression levels relative to those of the housekeeping gene GAPDH npg were determined on the basis of the comparative threshold cycle method (2 −∆∆CT ). The sequences for primers used in these experiments are given (Supplementary Table 9 ). All experiments were run in triplicate; results are representative of three independent experiments.
Immunohistochemistry. ERG rearrangement status was confirmed by immunohistochemistry, as previously described 54 . Briefly, primary rabbit monoclonal antibody to ERG was obtained from Epitomics (2805-1). Antigen recovery was conducted using heat retrieval and CC1 standard, a high pH Tris/borate/EDTA buffer (VMSI, 950-124). Slides were incubated with a 1:100 dilution of the primary antibody to ERG for 1 h at room temperature. Primary antibody was detected using the ChromoMap DAB detection kit (VMSI, 760-159) and UltraMap horseradish peroxidase (HRP)-conjugated secondary antibody to rabbit (VMSI, 760-4315). The secondary antibody was applied for 16 min at room temperature. Slides were counterstained with Hematoxylin II (VMSI, 790-2208) for 8 min and with Bluing Reagent (VMSI, 760-2037) for 4 min at 37 °C. Subjective evaluation of ERG protein expression was scored as positive or negative by pathologists for the study.
Plasmids expressing SPOP. Wild-type SPOP was obtained from Origene in a mammalian expression vector encoding C-terminal Myc and Flag tags. The sequence encoding SPOP F133V was created using the QuikChange II SiteDirected Mutagenesis kit (Agilent). The sequences of all plasmids were confirmed by Sanger sequencing, and protein expression was confirmed by protein blot using antibodies to Myc (Upstate, 05-724), and Flag (Sigma, F3165). 
